SAS and Carolina partner to accelerate antiviral drug development

Posted Nov 19, 2021
SAS, a leader in analytics and software services, and the University of North Carolina are teaming up to transform the drug development process to prevent infectious disease threats from turning into a pandemic like COVID-19. The partnership is focused on the work of the University’s Rapidly Emerging Antiviral Drug Development Initiative (READDI). (UNC.edu)

Related: Campus Connections

UNC-Founded Eats2Seats to Create Entrepreneurial ‘Third Space’ with New Franklin Street Headquarters
Like an Uber Eats for sports and entertainment venues, the concessions and vending partner Eats2Seats allows fans to order food and beverages right to their...
Tue Jun 9, 2026

'You can't escape the story': UNC class feels for indentations on Old East left by enslaved laborers
A class of first-year students spent an hour carefully running their hands along the grooves of Old East's brick exterior. Their goal? To find...
Sun Jun 7, 2026

Tasting the Town: The 'fryerarchy' of Chapel Hill
We have always said it is impossible to mess up french fries. However, we are also a proponent of the concept of a fry hierarchy...
Sat Jun 6, 2026

Chapel Hill-Carrboro Openings, Closings and Updates in January-March 2026
Kipos Greek Taverna returned to operations in Eastgate Crossing after months of restoration following Chantal’s flooding last summer. Located in the back corner of the...
Fri Jun 5, 2026